http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10585106-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ab4c5d509c2557162982bb79245c9b0e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-368 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2440-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2400-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-689 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2018-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d1f348b551a8e3c1967439180680f2f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7158a40a2356cc11edf79d3806335a2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff73167550a30ab321a66d65085686c6 |
| publicationDate | 2020-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-10585106-B2 |
| titleOfInvention | Detection and treatment of pregnancy complications comprising determining sialyl Lewis antigens and administering hCG |
| abstract | Disclosed herein is a method of identifying and/or addressing incipient preeclampsia in a patient-subject by the steps of (a) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a said patient-subject at about 25 weeks of pregnancy or earlier; (b) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a pregnant non-preeclampsia one or more subjects at about 30 weeks of pregnancy or later, wherein said at least one sialyl Lewis antigen assay is for a sialyl Lewis antigen assayed in step (a) is and if more than one subject is assayed, averaging said results; and (c) managing said patient-subject for preeclampsia, if said level of at least one sialyl Lewis antigen of step (a) is at or greater than about 20% above the level of such silalyl Lewis antigen assayed in step (b). |
| priorityDate | 2012-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 150.